<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01905124</url>
  </required_header>
  <id_info>
    <org_study_id>CF101-241UV</org_study_id>
    <nct_id>NCT01905124</nct_id>
  </id_info>
  <brief_title>Safety &amp;Efficacy of CF101 to Subjects With Uveitis</brief_title>
  <official_title>A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Daily CF101 Administered Orally to Subjects With Active, Sight-Threatening, Noninfectious Intermediate or Posterior Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Can-Fite BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Can-Fite BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, double-masked, placebo-controlled study subjects with active,&#xD;
      sight-threatening, noninfectious intermediate or posterior uveitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized, double-masked, placebo-controlled study in adult males and&#xD;
      females, aged 18 years and over, with active, sight-threatening, noninfectious intermediate&#xD;
      or posterior uveitis. Subjects will be randomly assigned to receive CF101 1 mg or matching&#xD;
      placebo tablets in a 2:1 ratio orally every 12 hours for 24 weeks.&#xD;
&#xD;
      At the Screening Visit (performed within 4 weeks prior to Baseline), subjects who provide&#xD;
      written informed consent will have a complete medical history, medication history, physical&#xD;
      examination, weight, sitting blood pressure, pulse rate, temperature, electrocardiogram&#xD;
      (ECG), clinical laboratory tests, and ophthalmologic examination, including biomicroscopy and&#xD;
      grading of uveitis activity. For assessment of uveitis activity and response to treatment,&#xD;
      fundus photography will be obtained according to a standardized procedure and interpreted at&#xD;
      the Uveitis Photograph Reading Center.&#xD;
&#xD;
      Subjects who successfully qualify will begin dosing with CF101 1 mg or placebo, to be taken&#xD;
      orally every 12 hours for 24 weeks. At the Baseline Visit, a PBMC sample will be obtained for&#xD;
      assessment of A3AR expression level. Subjects will return for safety and efficacy assessments&#xD;
      and a new supply of study medication at Weeks 2, 4, 8, 12, 16, 20, and for final assessment&#xD;
      and discharge at Week 24. A telephone call to each subject will be made at Week 26, for the&#xD;
      purpose of collecting information on adverse events (AEs) and concomitant medications.&#xD;
&#xD;
      During the course of the trial, concomitant use of intraocular or posterior subtenon&#xD;
      corticosteroids, intravitreal injections (including but not limited to steroids or&#xD;
      anti-vascular endothelial growth factors), systemic corticosteroids at a dose &gt;20 mg/day&#xD;
      prednisone equivalent, or monoclonal antibody therapy is prohibited. Systemic corticosteroid&#xD;
      and immunosuppressive regimens must remain stable throughout the course of the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The company has decided not to conduct the study&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 2019</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of uveitis on standardized photographic assessment</measure>
    <time_frame>24 weeks</time_frame>
    <description>Standardized fundus photographs will be obtained and uniformly assessed in a masked fashion at the Reading Center</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of CF101</measure>
    <time_frame>24 weeks</time_frame>
    <description>Frequency, nature, and severity of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Uveitis, Posterior</condition>
  <condition>Uveitis, Intermediate</condition>
  <arm_group>
    <arm_group_label>Drug: CF101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF101 1 mg q12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablets of CF101</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets q12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF101</intervention_name>
    <description>CF101 1 mg tablets orally every 12 hours for 24 weeks</description>
    <arm_group_label>Drug: CF101</arm_group_label>
    <other_name>IB-MECA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets orally every 12 hours for 24 weeks</description>
    <arm_group_label>Placebo tablets of CF101</arm_group_label>
    <other_name>Sugar pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, 18 years of age and over;&#xD;
&#xD;
          2. Diagnosis of active, sight-threatening, noninfectious intermediate or posterior&#xD;
             uveitis, as determined by the Standardization of Uveitis Nomenclature (SUN) Working&#xD;
             Group Criteria.&#xD;
&#xD;
          3. Vitreous haze in at least 1 eye (the &quot;study eye&quot;) of ≥Grade 3 on the &quot;Miami Scale&quot; at&#xD;
             the Screening Visit, as confirmed by the Uveitis Photograph Reading Center; ,&#xD;
&#xD;
          4. Best corrected visual acuity (BCVA) in the poorer seeing eye of 1.3 logarithm of the&#xD;
             minimum angle of resolution (logMAR) or better by Early Treatment Diabetic Retinopathy&#xD;
             Study (ETDRS; equivalent to 20/400) at Screening;&#xD;
&#xD;
          5. Requires, in the judgment of the Investigator, systemic therapy to treat uveitis;&#xD;
&#xD;
          6. No plans for elective ocular surgery during the trial duration;&#xD;
&#xD;
        10. Ability to understand and provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Primary diagnosis of anterior uveitis;&#xD;
&#xD;
          2. Uveitis of infectious etiology;&#xD;
&#xD;
          3. Presence of chorioretinal scars that are highly suspicious for ocular toxoplasmosis;&#xD;
&#xD;
          4. Confirmed or suspected uveitis of traumatic etiology;&#xD;
&#xD;
          5. Clinically suspected or confirmed central nervous system or ocular lymphoma;&#xD;
&#xD;
          6. Presence of any other form of ocular malignancy in the either eye including choroidal&#xD;
             melanoma;&#xD;
&#xD;
          7. Corneal or lens opacities or obscured ocular media other than vitreous haze upon&#xD;
             enrollment such that reliable clinical evaluations and grading of the posterior&#xD;
             segment cannot be performed;&#xD;
&#xD;
          8. Pupillary dilation inadequate for quality fundus photography;&#xD;
&#xD;
          9. Uncontrolled glaucoma or ocular hypertension in either eye, defined as intraocular&#xD;
             pressure (IOP) &gt;21 mm Hg while on medical therapy;&#xD;
&#xD;
         10. Chronic hypotony (IOP &lt;6 mm Hg) in either eye;&#xD;
&#xD;
         11. Presence of an ocular implantable steroid-eluting device;&#xD;
&#xD;
         12. Ocular injection of corticosteroid within 3 months prior to Baseline;&#xD;
&#xD;
         13. Use of Retisert within 6 months prior to baseline;&#xD;
&#xD;
         14. Use of the following within 90 days prior to Baseline or anticipated use to either eye&#xD;
             during the trial:&#xD;
&#xD;
               1. Intravitreal injections (including but not limited to steroids or anti-vascular&#xD;
                  endothelial growth factors), or&#xD;
&#xD;
               2. Posterior subtenon steroids;&#xD;
&#xD;
         15. YAG capsulotomy within 30 days prior to Day 1 in the study eye;&#xD;
&#xD;
         16. History of herpetic infection in the study eye or adnexa;&#xD;
&#xD;
         17. Oral corticosteroid dose &gt;20 mg/day prednisone equivalent;&#xD;
&#xD;
         18. Oral corticosteroid dose has been changed within 2 weeks prior to screening, or is&#xD;
             expected to change while on study;&#xD;
&#xD;
         19. Systemic immunosuppressive agent dose has been changed within 2 weeks prior to&#xD;
             screening;&#xD;
&#xD;
         20. Treatment with systemic monoclonal antibody within the longer of 1 month or 5 serum&#xD;
             half-lives, prior to screening;&#xD;
&#xD;
         21. Diagnosis or history of Behçet's Disease;&#xD;
&#xD;
         22. Any significant ocular disease that could compromise vision in either eye, including&#xD;
             but not limited to:&#xD;
&#xD;
               1. Diabetic retinopathy: proliferative diabetic retinopathy or non-proliferative&#xD;
                  diabetic retinopathy that compromise vision,&#xD;
&#xD;
               2. Wet age-related macular degeneration, and&#xD;
&#xD;
               3. Myopic degeneration with active subfoveal choroidal neovascularization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bnei-Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>July 14, 2013</study_first_submitted>
  <study_first_submitted_qc>July 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2013</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uveitis</keyword>
  <keyword>Intermediate uveitis</keyword>
  <keyword>Posterior uveitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Uveitis, Posterior</mesh_term>
    <mesh_term>Uveitis, Intermediate</mesh_term>
    <mesh_term>Pars Planitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

